Brink's wins UK CMA backing for remedy in planned NCR Atleos acquisition

• Brink’s agreed to buy NCR Atleos, with closing still expected early in the first quarter of 2027.
• UK competition officials accepted in principle a remedy to clear the deal without a deeper review.
• The remedy centers on divesting NoteMachine/TestLink UK, with a sale process under way and multiple buyers engaged.
• Brink’s reiterated its target of $200 million in annual run-rate cost synergies within three years of closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Brink's Company published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080509PRIMZONEFULLFEED9842083) on October 08, 2026, and is solely responsible for the information contained therein.